Januvia News
Most Popular Januvia Story
Januvia gets head-to-head rival in Onglyza
Watch out, Januvia. AstraZeneca and Bristol-Myers Squibb finally won FDA approval for their diabetes drug Onglyza, a DPP-4 inhibitor that will directly compete with Merck's fast-growing treatment. Read more...
Latest Headlines
- October 7, 2011
- June 27, 2011
- April 25, 2011
- November 8, 2010
- September 24, 2010
- July 14, 2010
- September 28, 2009
- August 3, 2009
- November 17, 2008
- November 14, 2008
- October 28, 2008
- September 10, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
